About Megakaryon
About Megakaryon
Company name
Megakaryon Corporation
Founded
September 9th, 2011
Locations
Kyoto office/Kyoto Lab
Kyoto Research Park,
93,Awatacho,Chudoji,
Shimogyo-ku,Kyoto,
600-8815,
JAPAN
Tokyo office
337 Bldg #1,
The University of Tokyo Institute of Medical Science
4-6-1,Shirokanedai,
Minato-ku,Tokyo,
108-8639,
JAPAN
Capitalization
¥5,070,120,000
Officers
  • Genjiro Miwa, MBACEO, President, and Founder
  • Motoo Watanabe, Ph.D.Chief Technology Officer
  • Kenichi Akamatsu, Ph.D.Chief Operating Officer
  • Koichi Samizo, MBA, Ph.D.Chief Strategy Officer

  • Koichi AshidaExternal Director
    (Innovation Network Corporation of Japan)
  • Takehiko SawabeExternal Auditor
    (Innovation Network Corporation of Japan)
  • Takeshi KawanoExternal Auditor
  • Tsuyoshi AyabeChief Financial Officer
  • Tomoyuki Inoue, Ph.D.Executive Officer, Head of CMC
  • Yoshihiro Kumagae, Ph.D.Executive Officer, Head of Regulatory & Clinical Affairs
  • Kosuke Ishii, CPA, CFEExecutive Officer, Head of Business Administration
Company Objectives
By utilizing the regenerative potential of induced pluripotent stem (iPS) cells, we aim to produce high-quality platelets and other blood products that are safe, with reliable supply on demand and are affordable while independent of blood donations.
Shareholders
Genjiro Miwa; Koji Eto; Hiromitsu Nakauchi; Motoo Watanabe; Kenichi Akamatsu; iPS Academia Japan, Inc.; iCELL Inc.; Innovation Network Corporation of Japan,; Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc.; Sysmex Corporation; CIMIC Holdings Co., Ltd.; Kyoto Seisakusho Co., Ltd.; Satake Chemical Equipment Mfg Ltd.; Shinsei Corporate Investment Ltd.; Miyako Capital.; Ltd. Mizuho Capital Co.; SMBC Venture Capital Co., Ltd.; Mitsubishi UFJ Capital Co., Ltd.; Japan Asia Investment Co., Ltd.; KSP, Inc.; Nissay Capital Co., Ltd.; DBJ Capital Co., Ltd.; The Shiga Bank Ltd.; REVIC Capital Co., Ltd.
Our Team (Brief Biographies of Officers)
Genjiro Miwa, MBA — CEO, President

Genjiro Miwa, MBA — CEO, President

  • 1974B.A.in Economics, University of Tokyo
  • 1974-82Mitsubishi Petrochemical(now Mitsubishi Chemical)
  • 1982-84MBA with Distinction, Harvard Business School
  • 1984-86Bain & Company
  • 1986-94Co-founder, BioSurface Technology (now a division of Sanofi)
  • 1986Co-founder & Director, Ardito Asset Management (present)
  • 2009Co-founder & President, iCELL (present)
Motoo Watanabe, Ph.D. — Chief Technology Officer

Motoo Watanabe, Ph.D. — Chief Technology Officer

  • 1974 B.A. in Agricultural Chemistry, University of Tokyo
  • 1974-2002 Mitsubishi Petrochemical(now Mitsubishi Chemical)
  • 1984-86 Canada Toronto Ontario Cancer Institute and Mount Sinai Hospital (Molecular Immunology Research as a Visiting Scientist)
  • 2003-07 Vice President and Advisor, CellFree Sciences
  • 2007-08 Coordinator of Industry-Academia-Government Cooperation, Tokyo University of Science
  • 2008-13 Technical Councilor, Japan Science and Technology Agency
  • 2009-13 Project Associate Support Specialist, Institute of Medical Science, University of Tokyo
  • 2009 Co-founder & Director, iCELL (present)
  • 2013-16 Program Manager, Japan Science and Technology Agency
  • 2016 Program Manager, Stem Cell Research, University of Tokyo Institute of Medical Science (present)
Kenichi Akamatsu, Ph.D. — Chief Operating Officer

Kenichi Akamatsu, Ph.D. — Chief Operating Officer

  • 1978B.S. in Biology, Okayama University
  • 1980M.S. in Biology, Okayama University
  • 1980-2013Chugai Pharmaceutical
  • 1981-84On assignment as Chair of Pathology, Tokai University School of Medicine, researching cellular immunity under Prof. Norikazu Tamaoki
  • 1996-2001Manager of Drug Discovery Research
  • 2001-08Assistant Head of CMC Planning & Promotion Dept. and Head of Regulatory Affairs,
  • 2008-12Director of Biotechnology Research
Koichi Samizo, MBA, Ph.D. — Chief Strategy Officer

Koichi Samizo, MBA, Ph.D. — Chief Strategy Officer

  • 1996B.E. in Biochemical Engineering, Gunma University
  • 2001Ph.D. in Medical Sciences, Gunma University Graduate School of Medicine
  • 2004MBA, Keio Business School
  • 2001-07Hisamitsu Pharmaceutical Co., Inc.
  • 2007-10Sandoz K.K.
  • 2010-16Meiji Seika Pharma Co., Ltd.
ScientificAdvisors/Collaborators
Hiromitsu Nakauchi

Hiromitsu Nakauchi, MD, Ph.D.

Director, Center for Stem Cell Biology and Regenerative Medicine, University of Tokyo
Professor of Genetics Institute for Stem Cell Biology and Regenerative Medicine, Stanford University

Koji Eto

Koji Eto, MD, Ph.D.

Professor of Center for iPS Cell Research and Application, Kyoto University
Professor of Research Center for Regenerative Therapeutics, Chiba University

George Q. Daley MD,Ph.D.

George Q. Daley MD,Ph.D.

Dean of Harvard Medical School,
Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; Director, Stem Cell Transplantation Program, Boston Children’s Hospital

Mahendra S. Rao MD,Ph.D.

Mahendra S. Rao MD,Ph.D.

Vice President for Regenerative Medicine, New York Stem Cell Foundation Research Institute
former Director of the NIH Center for Regenerative Medicine

Sherrill J. Slichter MD,Ph.D.

Sherrill J. Slichter MD,Ph.D.

Professor of Medicine, Division of Hematology, University of Washington School of Medicine

George J. Murphy MD,Ph.D.

George J. Murphy MD,Ph.D.

Asst. Professor of Medicine, Hematology and Oncology Section, Boston University School of Medicine

Alan D. Michelson、MD

Alan D. Michelson,MD

Professor of Medicine and Pediatrics, Harvard Medical School
Director, Center for Platelet Research Studies, Children's Hospital Boston
Joint appointment, Brigham and Women's Hospital

A.L. Larry Frelinger III, Ph.D

A.L. Larry Frelinger III, Ph.D

Assistant Professor of Pediatrics, Harvard Medical School
Associate Director, Center for Platelet Research Studies, Children's Hospital Boston
Joint Appointment, Dana Farber Cancer Institute

History

2011

  • September Megakaryon was founded to commercialize the research results of Prof. Nakauchi's and Prof. Eto's research teams that were recognized as an Adaptable and Seamless Technology Transfer Program through Target-driven Research and Development (A-STEP*) project under Japan Science and Technology (JST) Agency.Capital: 10 million.

2013

  • August Additional funding of ¥1,160 million raised through private shares managed by Innovation Network Corporation of Japan, SMBC Venture Capital Co., Ltd., Mizuho Capital Co., Ltd., and Mitsubishi UFJ Capital Co., Ltd.
  • September Kyoto Lab opened at the Kyoto University Hospital Campus.

2014

  • April Cell Processing Center (CPC) completed at the Kyoto Lab.
  • NovemberKyoto office/Kyoto Lab opened in Kyoto.

2015

  • MarchCompany officially recognized as a Designated Core Business within the Kansai National Strategic Special Zone.
  • March Additional ¥2,540 million raised through private shares managed by Innovation Network Corporation of Japan; SMBC Venture Capital Co., Ltd.; Mitsubishi UFJ Capital Co., Ltd.; Mizuho Capital Co., Ltd.; Japan Asia Investment Co., Ltd.; DBJ Capital Co., Ltd.; Nissay Capital Co., Ltd.; KSP, Inc.; and Miyako Capital.
  • November Commenced collaborative research with Harvard University (Boston Children's Hospital)

2016

  • April The Japan Agency for Medical Research and Development (AMED) has recognized our project for "Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine."
  • May Kyoto Office and Kyoto Lab expansion.

2017

  • June Featured at the Japan-US Innovation Awards Symposium, 2017 held at Stanford University.
  • December ¥3, 700 million raised through private shares managed by Innovation Network Corporation of Japan; Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc. Sysmex Corporation, CIMIC Holdings Co., Ltd., Kyoto Seisakusho Co., Ltd, Satake Chemical Equipment Mfg Ltd., Shinsei Corporate Investment Ltd., Miyako Capital Co., Mizuho Capital Co., The Shiga Bank Ltd., REVIC Capital Co., Ltd., SMBC Venture Capital Co., Ltd.; Mitsubishi UFJ Capital Co., Ltd.

2018

  • JuneMegakaryon selected for the J-Startup Program.
pagetop